Search research articles
Contact Us
Filters
Showing results (81-90 of 91) with videos related to
Page
of 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 16, 2001
Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients
Y Bécouarn, E Gamelin, B Coudert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 30, 2012
Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis
S Giacchetti, P A Dugué, P F Innominato, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 10, 2010
Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy
S Guiu, M Liegard, L Favier, et al.
Gynecologic Oncology
|
October 20, 1999
A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: a French anticancer federation study
C Lhommé, P Vennin, N Callet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 16, 2004
Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study
J-Y Douillard, R Gervais, G Dabouis, et al.
British Journal of Cancer
|
September 19, 2007
Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
C Massard, J-J Voigt, A Laplanche, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2000
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
S Giacchetti, B Perpoint, R Zidani, et al.
ESMO Open
|
December 25, 2021
IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer
O Molinier, B Besse, F Barlesi, et al.
Respiratory Medicine and Research
|
May 17, 2020
Somatic profile in lung cancers is associated to reproductive factors in never-smokers women: Results from the IFCT-1002 BioCAST study
C Fontaine-Delaruelle, J Mazières, J Cadranel, et al.
ESMO Open
|
July 25, 2021
Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME)
D Dano, A Lardy-Cleaud, A Monneur, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 91) with videos related to
Sort By:
Page
of 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 16, 2001
Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients
Y Bécouarn, E Gamelin, B Coudert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 30, 2012
Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis
S Giacchetti, P A Dugué, P F Innominato, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 10, 2010
Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy
S Guiu, M Liegard, L Favier, et al.
Gynecologic Oncology
|
October 20, 1999
A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: a French anticancer federation study
C Lhommé, P Vennin, N Callet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 16, 2004
Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study
J-Y Douillard, R Gervais, G Dabouis, et al.
British Journal of Cancer
|
September 19, 2007
Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
C Massard, J-J Voigt, A Laplanche, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2000
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
S Giacchetti, B Perpoint, R Zidani, et al.
ESMO Open
|
December 25, 2021
IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer
O Molinier, B Besse, F Barlesi, et al.
Respiratory Medicine and Research
|
May 17, 2020
Somatic profile in lung cancers is associated to reproductive factors in never-smokers women: Results from the IFCT-1002 BioCAST study
C Fontaine-Delaruelle, J Mazières, J Cadranel, et al.
ESMO Open
|
July 25, 2021
Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME)
D Dano, A Lardy-Cleaud, A Monneur, et al.
Page
of 10